Johnson & Johnson Discontinues Rheumatoid Arthritis Combination Therapy Development with AbbVie's Humira Due to Lack of Efficacy

Johnson & Johnson (JNJ.US) announced the termination of its experimental antibody drug nipocalimab in combination with anti-tumor necrosis factor alpha (anti-TNFα) therapy. The combination therapy was originally planned for the treatment of rheumatoid arthritis (RA). This decision was based on the results of its Phase 2a DAISY proof-of-concept study, which evaluated the effect of nipocalimab in combination with AbbVie's (ABBV.US) blockbuster drug Humira and other anti-TNFα therapies.

According to the 12-week trial data disclosed by Johnson & Johnson, although no new safety issues arose, the combination of nipocalimab and anti-TNFα therapy did not demonstrate a significant clinical benefit over anti-TNFα therapy alone in patients with rheumatoid arthritis.

The company clearly stated: "Based on these findings, Johnson & Johnson has decided not to proceed with the clinical development of this combination therapy in the RA treatment field."

As an important R&D project in Johnson & Johnson's rheumatology field, Nipocalimab was previously highly anticipated, with the company forecasting its non-risk-adjusted peak annual sales to exceed $5 billion. This setback highlights the high risks associated with innovative drug development, particularly in the highly competitive field of autoimmune disease treatment.

Notably, Humira, as the global pharmaceutical king, achieved nearly $21 billion in sales in 2021. However, it has faced sales pressure since 2023 due to the launch of biosimilars by American pharmaceutical companies such as Amgen.